EU Approves Daraxonrasib Pill for Advanced Pancreatic Cancer, Survival Doubles

Pancreatic cancer stands among the deadliest malignancies worldwide, prompting regulatory action on Tuesday when the European Commission approved daraxonrasib through an accelerated procedure for patients with advanced disease.

Developed by American start-up Revolution Medicines, the targeted pill addresses a therapeutic void for a disease where mortality rates remain exceptionally high, as reported by HLN.

The European Medicines Agency completed its scientific review in just over 100 days, cutting the standard 210-day timeline nearly in half, HLN noted. Data presented at the EORTC-NCI-AACR Symposium 2026 in Barcelona showed that combining standard chemotherapy with daraxonrasib kept tumor growth under control in 90.2 percent of metastatic pancreatic cancer patients, according to De Morgen.

Clinical trial results indicated that patients receiving the medication lived an average of 12.4 months, compared to 6.7 months with chemotherapy alone, as detailed by HLN.

“Dit onderzoek was voor mensen met uitgezaaide kanker die niet meer reageren op standaard chemotherapie. Zij zijn niet te genezen,” zei chirurg Marc Besselink van het Amsterdam UMC, zoals vermeld door RTL.nl. Besselink added that participating patients lived about twice as long as those receiving standard chemotherapy, describing the findings as exceptionally remarkable.

Daraxonrasib: A new pill for pancreatic cancer that nearly doubles the survival rate — ThePrint

Understanding Targeted RAS Inhibition

More than 90 percent of pancreatic tumors feature mutations in RAS genes, which act as molecular switches governing cell growth and division, De Morgen reported. Daraxonrasib functions as a RAS inhibitor designed to block the active form of these aberrant proteins. De Morgen said that shrinkage or complete disappearance of tumors occurred in 60.7 percent of patients, while De Telegraaf highlighted the wider consequences of these clinical milestones.

Unlike conventional chemotherapy, which damages healthy dividing cells such as mucosal tissue and blood components, targeted therapy intervenes directly in the molecular signaling pathways driving malignant proliferation. UZ Brussel oncologist Amy de Haar-Holleman explained to Het Belang van Limburg and Het Nieuwsblad that the medication acts on the faulty protein to step on the cellular brake and halt division.

Daraxonrasib First RAS Pill Nearly Doubles Pancreatic Cancer Survival — Druggable

Clinical Efficacy and Survival Data

Treatment Regimen Median Overall Survival One-Year Survival Rate
Standard Chemotherapy 6.6 months 17.0 percent
Daraxonrasib Plus Chemotherapy 13.2 months 53.2 percent

Data from clinical evaluations demonstrate notable survival improvements for patients with previously treated metastatic disease. Het Belang van Limburg and Het Nieuwsblad reported that median survival doubled from 6.6 months with standard regimens to 13.2 months when utilizing daraxonrasib. One-year survival reached 53.2 percent among patients taking the pill, compared to 17 percent under standard chemotherapy protocols, according to Het Belang van Limburg and Het Nieuwsblad.

Despite these findings, clinicians emphasize that the treatment does not cure the disease. De Morgen reported that scans showed no remaining trace of tumors in 8.2 percent of participants, a complete response that investigator Wungki Park of the Memorial Sloan Kettering Cancer Center described to the BBC as the closest approximation to a cure. Park said that patients experienced longer disease control and stronger tumor responses, which translate into extended survival.

Pancreatic Cancer Breakthrough: New Drug Daraxonrasib Nearly Doubles Survival — CNBC-TV18

Access Hurdles and Economic Realities

Following European approval, individual nations must negotiate reimbursement and pricing with Revolution Medicines, a process that can take up to sixteen months, according to Het Belang van Limburg and Het Nieuwsblad. Financial barriers remain substantial, with costs estimated at approximately 38,000 euros per month or 450,000 euros annually per patient, as reported by RTL.nl, Het Belang van Limburg, and Het Nieuwsblad.

Besselink noted to RTL.nl that Dutch patients cannot yet obtain prescriptions while administrative and pricing discussions proceed. Meanwhile, ongoing follow-up studies in specialized centers such as UZ Brussel aim to determine whether treatment-naive patients derive greater benefit from monotherapy with the pill or combined regimens, as reported by Het Belang van Limburg and Het Nieuwsblad.

References

  • European Medicines Agency (EMA) – Accelerated Assessment Procedures
  • Memorial Sloan Kettering Cancer Center – Clinical Research Presentations at EORTC-NCI-AACR Symposium 2026
  • Revolution Medicines – Clinical Development Data for RAS Inhibitors
Photo of author

Health Desk

Health Desk at Archyde.

5 Exercises for Women Over 65 Returning to Exercise

UCLA vs. Michigan Prediction, Odds, Picks: Win Secures Title Game Spot